Johnson & Johnson (NYSE:JNJ) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,639,368 shares of the company’s stock after acquiring an additional 102,502 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.73% of Johnson & Johnson worth $2,858,543,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Smithfield Trust Co boosted its holdings in shares of Johnson & Johnson by 5.2% in the third quarter. Smithfield Trust Co now owns 86,490 shares of the company’s stock valued at $14,006,000 after acquiring an additional 4,274 shares in the last quarter. DE Burlo Group Inc. acquired a new position in Johnson & Johnson during the 3rd quarter worth approximately $216,000. Pacer Advisors Inc. raised its stake in shares of Johnson & Johnson by 10.4% during the 3rd quarter. Pacer Advisors Inc. now owns 265,688 shares of the company’s stock worth $43,057,000 after buying an additional 25,083 shares in the last quarter. Integrated Investment Consultants LLC boosted its stake in shares of Johnson & Johnson by 1,578.5% in the third quarter. Integrated Investment Consultants LLC now owns 65,312 shares of the company’s stock valued at $10,584,000 after buying an additional 61,421 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Johnson & Johnson by 10.2% during the third quarter. LPL Financial LLC now owns 3,714,260 shares of the company’s stock worth $601,933,000 after acquiring an additional 344,641 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $153.10 on Thursday. The stock has a 50 day simple moving average of $160.59 and a 200-day simple moving average of $156.17. The company has a market cap of $368.61 billion, a PE ratio of 22.16, a P/E/G ratio of 2.72 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.66 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JNJ shares. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Guggenheim upped their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.